How does SYNT's PE Ratio compare to its peers?

SYNT is expensive based on its Price-To-Earnings Ratio (115.3x) compared to the peer average (53.2x).

How does SYNT's PE Ratio compare vs other companies in the European Healthcare Services Industry?

SYNT is expensive based on its Price-To-Earnings Ratio (115.3x) compared to the European Healthcare Services industry average (26.3x).

What is SYNT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYNT is expensive based on its Price-To-Earnings Ratio (115.3x) compared to the estimated Fair Price-To-Earnings Ratio (46.5x).

What is the Fair Price of SYNT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SYNT (SEK27.7) is trading below our estimate of [[fair value]] (SEK42.22)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

SyntheticMR (NGM:SYNT) - Stock Price, News & Analysis

SYNT Stock Overview

Engages in the development and marketing of imaging solutions for magnetic resonance imaging (MRI) in Sweden, the Middle East, Africa, Europe, North America, South America, and the Asia-Pacific. More details

SYNT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 34.4% below our estimate of its fair value

Earnings are forecast to grow 47.4% per year

Earnings grew by 70.3% over the past year

Risk Analysis

Shares are highly illiquid

High level of non-cash earnings

SyntheticMR AB (publ) Competitors

RaySearch Laboratories

OM:RAY B

SEK 6.4b

Physitrack

OM:PTRK

SEK 130.1m

Kontigo Care

OM:KONT

SEK 103.8m

Sectra

OM:SECT B

SEK 54.9b

Price History & Performance

Summary of all time highs, changes and price drops for SyntheticMR
Historical stock prices
Current Share Price	SEK 27.70
52 Week High	SEK 34.90
52 Week Low	SEK 17.30
Beta	0.96
11 Month Change	0%
3 Month Change	1.09%
1 Year Change	-13.44%
33 Year Change	-40.69%
5 Year Change	6.54%
Change since IPO	1,008.00%

Recent updates

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Nov 29

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Aug 06

Why SyntheticMR AB (publ) (NGM:SYNT) Could Be Worth Watching

Feb 23

A Look At The Intrinsic Value Of SyntheticMR AB (publ) (NGM:SYNT)

Jan 27

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

Nov 10

Read This Before Selling SyntheticMR AB (publ) (NGM:SYNT) Shares

Mar 09

What Percentage Of SyntheticMR AB (publ) (NGM:SYNT) Shares Do Insiders Own?

Feb 11

SyntheticMR AB (publ) (NGM:SYNT) Insiders Increased Their Holdings

Dec 03

Shareholder Returns

	SYNT	SE Healthcare Services	SE Market
7D	0%	-5.8%	-2.6%
1Y	-13.4%	50.5%	13.6%

Return vs Industry: SYNT underperformed the Swedish Healthcare Services industry which returned 34.5% over the past year.

Return vs Market: SYNT underperformed the Swedish Market which returned 8.6% over the past year.

Price Volatility

Is SYNT's price volatile compared to industry and market?
SYNT volatility
SYNT Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	5.9%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.3%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: SYNT has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine SYNT's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	37	Ulrik Harrysson	www.syntheticmr.com

SyntheticMR AB (publ) engages in the development and marketing of imaging solutions for magnetic resonance imaging (MRI) in Sweden, the Middle East, Africa, Europe, North America, South America, and the Asia-Pacific. Its SyMRI delivers various contrast images, biomarker segmentations, and quantitative data with a single MR sequence. The company also offers SyMRI NEURO includes contrast weighted images, as well as biomarker segmentation, volumetric measurements of brain tissues and parametric maps that provide objective decision support for the diagnosis and follow-up of patients; SyMRI MSK works on a range of anatomies, and provides quantitative T1, T2, and PD maps, as well as multiple contrast-weighted images; and MAGiC, a customer-specific version of SyMRI IMAGE.

SyntheticMR AB (publ) Fundamentals Summary

How do SyntheticMR's earnings and revenue compare to its market cap?
SYNT fundamental statistics
Market cap	SEK 1.15b
Earnings (TTM)	SEK 10.01m
Revenue (TTM)	SEK 94.37m

115.3x

P/E Ratio

12.2x

P/S Ratio

Is SYNT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SYNT income statement (TTM)
Revenue	SEK 94.37m
Cost of Revenue	SEK 30.33m
Gross Profit	SEK 64.05m
Other Expenses	SEK 54.03m
Earnings	SEK 10.01m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 21, 2024

Earnings per share (EPS)	0.24
Gross Margin	67.86%
Net Profit Margin	10.61%
Debt/Equity Ratio	0%

How did SYNT perform over the long term?

See historical performance and comparison

SYNT Stock Overview

Rewards

Risk Analysis

SyntheticMR AB (publ) Competitors

OM:RAY B

SEK 6.4b

OM:PTRK

SEK 130.1m

OM:KONT

SEK 103.8m

OM:SECT B

SEK 54.9b

Price History & Performance

Recent News & Updates

SyntheticMR AB Receives Regulatory Approval for SyMRI 15 in Australia

SyntheticMR AB (publ) to Report Q3, 2024 Results on Nov 19, 2024

SyntheticMR Announces Appointment of Francois Hebert as New President, North America

SyntheticMR Receives Regulatory Approval for Symri in Taiwan

SyntheticMR AB (publ) to Report Q2, 2024 Results on Aug 27, 2024

SyntheticMR AB (publ) Announces Board Changes

Recent updates

SyntheticMR AB Receives Regulatory Approval for SyMRI 15 in Australia

SyntheticMR AB (publ) to Report Q3, 2024 Results on Nov 19, 2024

SyntheticMR Announces Appointment of Francois Hebert as New President, North America

SyntheticMR Receives Regulatory Approval for Symri in Taiwan

SyntheticMR AB (publ) to Report Q2, 2024 Results on Aug 27, 2024

SyntheticMR AB (publ) Announces Board Changes

SyntheticMR AB (publ) to Report Q1, 2024 Results on May 21, 2024

SyntheticMR AB (publ), Annual General Meeting, May 21, 2024

SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D

SyntheticMR AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

Should You Think About Buying SyntheticMR AB (publ) (NGM:SYNT) Now?

SyMRI 3D by SyntheticMR Set for Early 2024 Commercial Launch Post Obtaining CE-Marking

SyntheticMR Has Submitted Their Next Generation Solution, SyMRI 3D for 510(K) Clearance

SyntheticMR Appoints Nomination Committee for the 2024 Annual General Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

SyntheticMR AB (publ) to Report Nine Months, 2023 Results on Nov 10, 2023

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued after recent price drop

SyntheticMR AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Now 20% undervalued after recent price drop

SyntheticMR Releases A New Update to SyMRI 11.3.11 & 12.1.11

SyntheticMR Introduces Quantitative Neuro Reports to Enhance Clinical Workflow

SyntheticMR Receives Regulatory Approval for Their Innovative SyMRI Software Solution in South Korea

Consensus EPS estimates fall by 28%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Some Investors May Be Worried About SyntheticMR's (NGM:SYNT) Returns On Capital

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

Full year 2022 earnings released: EPS: kr0.15 (vs kr0.20 in FY 2021)

Now 24% undervalued after recent price drop

SyntheticMR AB (publ), Annual General Meeting, May 23, 2023

Consensus EPS estimates fall by 17%

Now 21% undervalued after recent price drop

SyntheticMR AB (publ) to Report Fiscal Year 2022 Results on Feb 15, 2023

Now 20% undervalued after recent price drop

There Are Reasons To Feel Uneasy About SyntheticMR's (NGM:SYNT) Returns On Capital

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

No independent directors

Now 21% undervalued after recent price drop

SyntheticMR Receives EU Medical Device Regulation (Mdr) Certificate

SyntheticMR AB (publ) to Report Q3, 2022 Results on Nov 16, 2022

SyntheticMR's SyMRI MSK Software for Knee and Spine Imaging Receives Regulatory Approval in Brazil

Consensus EPS estimates increase by 18%

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia

Consensus EPS estimates fall by 14%

Consensus EPS estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

What Does SyntheticMR AB (publ)'s (NGM:SYNT) Share Price Indicate?

SyntheticMR AB (publ) to Report First Half, 2022 Results on Aug 23, 2022

SyntheticMR's Quantitative MRI Solution Symri Neuro Compatible with Philips Smartspeed to Support Shorter Scan Times

Dr. Jeff Miller Joins SyntheticMR's Medical Advisory Board

SyMRI MSK from SyntheticMR is Now Available on syngo.via Open Apps from Siemens Healthineers

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 19%

Price target decreased to kr36.00

No independent directors